IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Immunovant, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$27.62+0.89 (+3.33%)
Close on Oct 19, 2026
- Market cap
- $5.68B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$10.11 (+57.74%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $5.68B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 7.72
- Dividend yield
- –
- Free cash flow yield
- -7.17%
Fundamentals
- Net income
- -$538.22M
- EPS, diluted
- -$2.82
- Free cash flow
- -$407.32M
- Book value per share
- $3.58
- Diluted shares
- 206M
Nine years at a glance
Fiscal years 2018 to 2026 and trailing twelve months, USD
Net income
-$538.22M
EPS, diluted
-$2.82
Free cash flow
–
Reported periodTrailing twelve months